Promising Gene Therapy Helps Reduce Transfusion In Patients With Blood Disorders

People with beta-thalassemia, a genetic blood disorder, could benefit from a promising gene therapy. The therapy, LentiGlobin, is reported to reduce or eliminate the need for blood transfusions in patients enrolled in Phase 1 and 2 trials.